Review Article | Published:

Clinical blockade of PD1 and LAG3 — potential mechanisms of action

Nature Reviews Immunology volume 15, pages 4556 (2015) | Download Citation

Abstract

Dysfunctional T cells can render the immune system unable to eliminate infections and cancer. Therapeutic targeting of the surface receptors that inhibit T cell function has begun to show remarkable success in clinical trials. In this Review, we discuss the potential mechanisms of action of the clinical agents that target two of these receptors, programmed cell death protein 1 (PD1) and lymphocyte activation gene 3 protein (LAG3). We also suggest correlative studies that may define the predominant mechanisms of action and identify predictive biomarkers.

Key points

  • Negative regulatory receptors, such as PD1 and LAG3, are expressed on 'exhausted' T cells. However, not all cells that express these receptors are exhausted. Therapeutic blockade of the PD1 pathway shows durable clinical responses in patients with melanoma and other types of cancer.

  • The presumed mechanism of action of PD1 blockade is prevention of the interaction between PD1 on tumour-infiltrating T cells and PDL1 expressed on tumour cells. However, PDL1 expression by tumour cells is not an absolute biomarker of clinical response.

  • PD1 has many other functions and pathways that could also be affected by PD1–PDL1 blockade: for example, PD1 and PDL1 are expressed by a variety of cell types in response to a variety of stimuli. PD1 blockade may also perturb other receptor–ligand interactions. Furthermore, 'reverse signalling' can occur through PDL1.

  • The clinical activity of blocking LAG3 is not yet known, but this could potentially induce anti-tumour responses.

  • Triggering of LAG3 on T cells by MHC class II ligands downregulates T cell function, but may also have other immunomodulatory roles. In addition, soluble LAG3 exhibits immune adjuvant activity.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    T cell exhaustion. Nature Immunol. 12, 492–499 (2011).

  2. 2.

    et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27, 670–684 (2007). This study defines the gene expression profile of T cells during chronic versus acute LCMV infection.

  3. 3.

    , , , & Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice: role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 60, 521–540 (1984).

  4. 4.

    et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682–687 (2006). This study shows in the LCMV clone 13 infection model that PD1 blockade can reverse T cell exhaustion and clear chronic viral infection.

  5. 5.

    et al. PD1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 203, 2281–2292 (2006).

  6. 6.

    et al. Upregulation of PD1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nature Med. 12, 1198–1202 (2006).

  7. 7.

    et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350–354 (2006). References 5–7 show the importance of PD1 in the dysfunction of HIV-specific T cells.

  8. 8.

    et al. TIM3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 205, 2763–2779 (2008).

  9. 9.

    et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nature Immunol. 10, 29–37 (2009).

  10. 10.

    et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG3 and PD1 in human ovarian cancer. Proc. Natl Acad. Sci. USA 107, 7875–7880 (2010).

  11. 11.

    et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J. Clin. Invest. 120, 157–167 (2010).

  12. 12.

    et al. Upregulation of TIM3 and PD1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207, 2175–2186 (2010).

  13. 13.

    et al. Targeting TIM3 and PD1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187–2194 (2010).

  14. 14.

    et al. Coexpression of PD1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 6, e1000947 (2010).

  15. 15.

    et al. CD160 and PD1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog. 8, e1002840 (2012).

  16. 16.

    et al. CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD1. Cancer Res. 72, 887–896 (2012).

  17. 17.

    et al. PD1 dependent exhaustion of CD8+ T cells drives chronic malaria. Cell Rep. 5, 1204–1213 (2013).

  18. 18.

    , , & HTLV-1 specific CD8+ T cell function augmented by blockade of 2B4/CD48 interaction in HTLV-1 infection. PLoS ONE 9, e87631 (2014).

  19. 19.

    et al. Exhaustion of tumor-specific CD8 T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350–2360 (2011).

  20. 20.

    et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS ONE 7, e30852 (2012).

  21. 21.

    & CD28 and CTLA4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459–465 (1995).

  22. 22.

    et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA4. Science 270, 985–988 (1995).

  23. 23.

    et al. Loss of CTLA4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA4. Immunity 3, 541–547 (1995).

  24. 24.

    et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303–310 (2000).

  25. 25.

    , & Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295–302 (2000).

  26. 26.

    , , , & Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206, 1717–1725 (2009).

  27. 27.

    et al. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity 6, 583–589 (1997).

  28. 28.

    , , & Induced expression of PD1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887–3895 (1992).

  29. 29.

    , , & B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Med. 5, 1365–1369 (1999).

  30. 30.

    et al. Engagement of the PD1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).

  31. 31.

    et al. PDL2 is a second ligand for PD1 and inhibits T cell activation. Nature Immunol. 2, 261–268 (2001).

  32. 32.

    et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193, 839–846 (2001).

  33. 33.

    , , & PD1 and its ligands in tolerance and immunity. Ann. Rev. Immunol. 26, 677–704 (2008).

  34. 34.

    & The PD1-PDL pathway in immunological tolerance. Trends Immunol. 27, 195–201 (2006).

  35. 35.

    , , , & A rheostat for immune responses: the unique properties of PD1 and their advantages for clinical application. Nature Immunol. 14, 1212–1218 (2013).

  36. 36.

    et al. Involvement of PDL1 on tumor cells in the escape from host immune system and tumor immunotherapy by PDL1 blockade. Proc. Natl Acad. Sci. USA 99, 12293–12297 (2002).

  37. 37.

    et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med. 8, 793–800 (2002).

  38. 38.

    & Antagonist antibodies to PD1 and B7-H1 (PDL1) in the treatment of advanced human cancer. Clin. Cancer Res. 19, 1021–1034 (2013).

  39. 39.

    et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD1), in patients with chronic hepatitis C virus infection. PLoS ONE 8, e63818 (2013).

  40. 40.

    et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010).

  41. 41.

    et al. Safety, activity, and immune correlates of anti–PD1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).

  42. 42.

    et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).

  43. 43.

    et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 31, 4311–4318 (2013).

  44. 44.

    et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020–1030 (2014). This paper is the most recently published follow-up report on data from the nivolumab clinical trials, showing durable clinical responses in patients with metastatic melanoma.

  45. 45.

    et al. Safety and tumor responses with lambrolizumab (anti-PD1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013).

  46. 46.

    et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384, 1109–1117 (2014). This paper is the most recent published update from a pembrolizumab clinical trial.

  47. 47.

    et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044–3051 (2008). This is the first-in-human clinical trial of PD1 pathway blockade that was published.

  48. 48.

    et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 31, 4199–4206 (2013).

  49. 49.

    et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 15, 69–77 (2014).

  50. 50.

    et al. Safety and activity of anti–PDL1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).

  51. 51.

    et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab. Invest. 94, 107–116 (2014).

  52. 52.

    et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4, 127ra37 (2012).

  53. 53.

    et al. PDL1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol. Res. 1, 54–63 (2013).

  54. 54.

    et al. Upregulation of PD-L1, IDO, and TRegs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5, 200ra116 (2013).

  55. 55.

    et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170, 1257–1266 (2003).

  56. 56.

    et al. The common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 181, 6738–6746 (2008).

  57. 57.

    et al. Cutting edge: IFNγ enables APC to promote memory TH17 and abate TH1 cell development. J. Immunol. 181, 5842–5846 (2008).

  58. 58.

    , , , & Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2, e25961 (2013).

  59. 59.

    et al. PDL1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J. Clin. Invest. 120, 2508–2515 (2010).

  60. 60.

    et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Med. 9, 562–567 (2003).

  61. 61.

    et al. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD1–PDL1 axis. Cancer Res. 74, 3441–3453 (2014).

  62. 62.

    et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25hi regulatory T cells. Int. Immunol. 21, 1065–1077 (2009).

  63. 63.

    et al. PDL1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015–3029 (2009). This study describes the importance of PDL1 in the development and the maintenance of pTReg cells.

  64. 64.

    & B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol. 169, 3581–3588 (2002).

  65. 65.

    et al. Endothelial expression of PDL1 and PDL2 downregulates CD8+ T cell activation and cytolysis. Eur. J. Immunol. 33, 3117–3126 (2003).

  66. 66.

    et al. Endothelial programmed death-1 ligand 1 (PDL1) regulates CD8+ T-cell mediated injury in the heart. Circulation 116, 2062–2071 (2007).

  67. 67.

    , , , & Programmed death ligand 2 in cancer-induced immune suppression. Clin. Dev. Immunol. 2012, 656340 (2012).

  68. 68.

    et al. RGMB is a novel binding partner for PDL2 and its engagement with PDL2 promotes respiratory tolerance. J. Exp. Med. 211, 943–959 (2014).

  69. 69.

    et al. PD1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J. Exp. Med. 210, 757–774 (2013).

  70. 70.

    et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698–2703 (2008).

  71. 71.

    et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).

  72. 72.

    et al. Inhibitory phenotype of HBV-specific CD4+ T-cells is characterized by high PD1 expression but absent coregulation of multiple inhibitory molecules. PLoS ONE 9, e105703 (2014).

  73. 73.

    et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123, 2873–2892 (2013).

  74. 74.

    et al. PD1 on dendritic cells impedes innate immunity against bacterial infection. Blood 113, 5811–5818 (2009).

  75. 75.

    et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nature Med. 16, 452–459 (2010).

  76. 76.

    et al. Myeloid-derived suppressor cells regulate immune response in patients with chronic hepatitis B virus infection through PD1-Induced IL-10. J. Immunol. 193, 5461–5469 (2014).

  77. 77.

    et al. Blockade of B7-H1 and PD1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65, 1089–1096 (2005).

  78. 78.

    et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111, 3635–3643 (2008).

  79. 79.

    et al. Contribution of the PD1 ligands/PD1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur. J. Immunol. 36, 2472–2482 (2006).

  80. 80.

    et al. PDL1 is a novel direct target of HIF1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781–790 (2014).

  81. 81.

    et al. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J. Infect. Dis. 202, 524–532 (2010).

  82. 82.

    et al. PD1 expression on natural killer cells and CD8+ T cells during chronic HIV-1 infection. Viral Immunol. 25, 329–332 (2012).

  83. 83.

    , , , & Activation of human lymphocytes by a monoclonal antibody to B lymphoblastoid cells; molecular mass and distribution of binding protein. Cancer Immunol. Immunother. 40, 376–382 (1995).

  84. 84.

    et al. The PD1/PDL1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD1 antibody. Blood 116, 2286–2294 (2010).

  85. 85.

    , , , & Development of lupus-like autoimmune diseases by disruption of the PD1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141–151 (1999). This paper is the first description of the role of PD1 in autoimmunity.

  86. 86.

    et al. Autoimmune dilated cardiomyopathy in PD1 receptor-deficient mice. Science 291, 319–322 (2001).

  87. 87.

    et al. Role of CXCR5 and CCR7 in follicular TH cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation. J. Immunol. 179, 5099–5108 (2007).

  88. 88.

    et al. PD1 is a novel regulator of human B-cell activation. Int. Immunol. 25, 129–137 (2013).

  89. 89.

    et al. Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. Proc. Natl Acad. Sci. USA 109, 10468–10473 (2012).

  90. 90.

    et al. Acute depletion of activated memory B cells involves the PD1 pathway in rapidly progressing SIV-infected macaques. J. Clin. Invest. 120, 3878–3890 (2010).

  91. 91.

    , , , & Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111–122 (2007).

  92. 92.

    et al. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD1 interaction. J. Exp. Med. 197, 1083–1091 (2003).

  93. 93.

    et al. B7DC/PDL2 promotes tumor immunity by a PD1-independent mechanism. J. Exp. Med. 197, 1721–1730 (2003).

  94. 94.

    et al. Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD1 receptor. J. Exp. Med. 198, 31–38 (2003).

  95. 95.

    et al. Association of PD1, PD1 ligands, and other features of the tumor immune microenvironment with response to anti-PD1 therapy. Clin. Cancer Res. 20, 5064–5074 (2014).

  96. 96.

    et al. LAG3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 171, 1393–1405 (1990). This paper describes the identification of LAG3.

  97. 97.

    , , , & Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG3). Eur. J. Immunol. 32, 2255–2263 (2002).

  98. 98.

    , & The CD4-like molecule LAG3, biology and therapeutic applications. Expert Opin. Ther. Targets 15, 91–101 (2011).

  99. 99.

    , , , & Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur. J. Immunol. 24, 3216–3221 (1994).

  100. 100.

    et al. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J. Immunol. 172, 5450–5455 (2004).

  101. 101.

    , & On the role of the inhibitory receptor LAG3 in acute and chronic LCMV infection. Int. Immunol. 22, 13–23 (2010).

  102. 102.

    et al. Therapeutic blockade of PDL1 and LAG3 rapidly clears established blood-stage Plasmodium infection. Nature Immunol. 13, 188–195 (2012).

  103. 103.

    , , , & Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG3): role of LAG3/MHC class II interactions in cell-cell contacts. Eur. J. Cancer 37, 1709–1718 (2001).

  104. 104.

    et al. LAG3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J. Clin. Invest. 117, 3383–3392 (2007).

  105. 105.

    et al. Immune inhibitory molecules LAG3 and PD1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917–927 (2012).

  106. 106.

    et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J. Immunol. 190, 4899–4909 (2013).

  107. 107.

    et al. Role of LAG3 in regulatory T cells. Immunity 21, 503–513 (2004).

  108. 108.

    et al. Role of lymphocyte activation gene-3 (LAG3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS ONE 9, e86551 (2014).

  109. 109.

    , , & Expression of lymphocyte activation gene 3 (LAG3) on B cells is induced by T cells. Eur. J. Immunol. 35, 2081–2088 (2005).

  110. 110.

    & Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J. Immunol. 174, 688–695 (2005).

  111. 111.

    et al. MHC class II engagement by its ligand LAG3 (CD223) contributes to melanoma resistance to apoptosis. J. Immunol. 186, 5173–5183 (2011).

  112. 112.

    , , , & A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J. Immunol. 179, 4202–4211 (2007). This paper describes the soluble LAG3 reagent that went on to be tested for immune adjuvant activity in clinical trials.

  113. 113.

    , , & Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses. Eur. J. Immunol. 29, 3867–3876 (1999).

  114. 114.

    et al. Soluble human LAG3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. Cancer Res. 66, 4450–4460 (2006).

  115. 115.

    , & A soluble lymphocyte activation gene-3 (sLAG3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett. 235, 147–153 (2006).

  116. 116.

    , , , & IMP321 (sLAG3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study. Vaccine 25, 4641–4650 (2007).

  117. 117.

    , , , & A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin. Cancer Res. 15, 6225–6231 (2009).

  118. 118.

    et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG3Ig) enhances immune responses and antitumor activity. J. Transl. Med. 8, 71 (2010).

  119. 119.

    et al. MART1 peptide vaccination plus IMP321 (LAG3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J. Transl. Med. 12, 97 (2014).

  120. 120.

    et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).

  121. 121.

    et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562 (2014).

  122. 122.

    et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).

  123. 123.

    et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. (2014).

Download references

Acknowledgements

The authors thank O. Chan for her contributions to this article.

Author information

Affiliations

  1. Immune Therapy Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.

    • Linh T. Nguyen
    •  & Pamela S. Ohashi

Authors

  1. Search for Linh T. Nguyen in:

  2. Search for Pamela S. Ohashi in:

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Linh T. Nguyen or Pamela S. Ohashi.

Glossary

Exhaustion

A state of impaired T cell function that results from chronic exposure to an antigen.

Inhibitory receptors

Receptors that negatively regulate cellular function. They may contain immunoreceptor tyrosine-based inhibition (ITIM) motifs. The absence of such receptors or their inhibition by antagonistic antibodies leads to improved cell function.

Merkel cell

A cell type in the epithelium that is essential for the fine resolution of sensory stimuli; this cell type is malignantly transformed in Merkel cell carcinoma.

Two-photon intravital microscopy

Laser-scanning microscopy that uses near-infrared laser light for the excitation of conventional fluorophores or fluorescent proteins. Owing to the deep tissue penetration of light, the main advantage is the ability to visualize live and intact specimens.

T follicular helper cells

(TFH cells). CD4+ T helper cells that function in providing help for B cell responses, including the formation of germinal centres and differentiation of B cells into antibody-producing plasma cells.

Germinal centre

Located in peripheral lymphoid tissues (for example, the spleen), these structures are sites of B cell proliferation and selection for clones that produce antigen-specific antibodies of higher affinity.

Recombination-activating gene

(RAG). RAG1 and RAG2 are essential for the rearrangement process that generates diversity in T cell receptor and antibody loci. Mice that are deficient for either of these genes fail to produce B cells or T cells owing to a developmental block in the gene rearrangement that is necessary for antigen receptor expression.

Objective responses

Reductions in tumour burden that satisfy the criteria for a complete or partial response.

Trogocytosis

A process in which a cell can acquire portions of the cell membrane and molecules within the membrane from another cell. The term is generally used for immune cells.

Adjuvant

An agent that improves an immune response, generally acting via stimulating antigen-presenting cells.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nri3790

Further reading